ABIONYX Pharma SA (ABNX.PA)
EUR 1.25
(2.46%)
EUR 1.25
(2.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.64 Million EUR | -11.65% |
| 2022 | 5.25 Million EUR | 678.07% |
| 2021 | 675 Thousand EUR | 0.0% |
| 2020 | - EUR | 0.0% |
| 2019 | - EUR | -100.0% |
| 2018 | 174 Thousand EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| 2016 | - EUR | 0.0% |
| 2015 | - EUR | 0.0% |
| 2014 | - EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.34 Million EUR | 0.0% |
| 2023 Q4 | 1.25 Million EUR | 0.0% |
| 2023 FY | 4.64 Million EUR | -11.65% |
| 2023 Q1 | 1.06 Million EUR | -59.42% |
| 2023 Q2 | 2.12 Million EUR | 100.0% |
| 2023 Q3 | 1.25 Million EUR | -40.98% |
| 2022 Q3 | 1.31 Million EUR | -50.15% |
| 2022 Q2 | 2.63 Million EUR | 100.0% |
| 2022 Q1 | 1.31 Million EUR | 102.93% |
| 2022 Q4 | 2.62 Million EUR | 100.0% |
| 2022 FY | 5.25 Million EUR | 678.07% |
| 2021 Q2 | 27 Thousand EUR | 100.0% |
| 2021 Q3 | 324 Thousand EUR | 1100.0% |
| 2021 Q4 | 648 Thousand EUR | 100.0% |
| 2021 FY | 675 Thousand EUR | 0.0% |
| 2021 Q1 | 13.5 Thousand EUR | 0.0% |
| 2020 FY | - EUR | 0.0% |
| 2020 Q4 | - EUR | 0.0% |
| 2020 Q3 | - EUR | 0.0% |
| 2020 Q2 | - EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2019 FY | - EUR | -100.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2019 Q4 | - EUR | 0.0% |
| 2019 Q2 | - EUR | 0.0% |
| 2019 Q3 | - EUR | 0.0% |
| 2018 Q2 | - EUR | 0.0% |
| 2018 Q1 | - EUR | 0.0% |
| 2018 FY | 174 Thousand EUR | 0.0% |
| 2018 Q4 | 87 Thousand EUR | 0.0% |
| 2018 Q3 | 87 Thousand EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| 2017 Q3 | - EUR | 0.0% |
| 2017 Q4 | - EUR | 0.0% |
| 2017 Q1 | - EUR | 0.0% |
| 2017 Q2 | - EUR | 0.0% |
| 2016 Q2 | - EUR | 0.0% |
| 2016 Q4 | - EUR | 0.0% |
| 2016 Q3 | - EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 FY | - EUR | 0.0% |
| 2015 FY | - EUR | 0.0% |
| 2015 Q1 | - EUR | 0.0% |
| 2015 Q3 | - EUR | 0.0% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | - EUR | 0.0% |
| 2014 Q4 | - EUR | 0.0% |
| 2014 Q2 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIVAX Société Anonyme | 4.62 Million EUR | -0.411% |
| Adocia SA | 2.15 Million EUR | -115.814% |
| Aelis Farma SA | 9.05 Million EUR | 48.752% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -47.255% |
| genOway Société anonyme | 20.04 Million EUR | 76.854% |
| IntegraGen SA | 12.53 Million EUR | 62.991% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -1446.491% |
| Neovacs S.A. | 533.41 Thousand EUR | -769.872% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -175.942% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -23339.079% |
| Sensorion SA | 4.74 Million EUR | 2.173% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -1465.817% |
| TME Pharma N.V. | 17 Thousand EUR | -27194.118% |
| Valbiotis SA | 4.73 Million EUR | 1.965% |
| TheraVet SA | 1.07 Million EUR | -330.405% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -157.778% |
| argenx SE | 1.13 Billion EUR | 99.591% |
| BioSenic S.A. | 543 Thousand EUR | -754.512% |
| Celyad Oncology SA | 102 Thousand EUR | -4449.02% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 98.064% |
| Genfit S.A. | 28.56 Million EUR | 83.756% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -122.329% |
| Innate Pharma S.A. | 51.9 Million EUR | 91.06% |
| Inventiva S.A. | 17.47 Million EUR | 73.451% |
| MaaT Pharma SA | 2.22 Million EUR | -108.259% |
| MedinCell S.A. | 9.16 Million EUR | 49.345% |
| Nanobiotix S.A. | 30.05 Million EUR | 84.563% |
| Onward Medical N.V. | 532 Thousand EUR | -772.18% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 67.305% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -108.352% |
| Oxurion NV | 263 Thousand EUR | -1664.259% |
| Pharming Group N.V. | 245.31 Million EUR | 98.109% |
| Poxel S.A. | 1.98 Million EUR | -134.225% |
| GenSight Biologics S.A. | 1.26 Million EUR | -266.219% |
| Transgene SA | 1.18 Million EUR | -291.892% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.912% |
| Valneva SE | 153.71 Million EUR | 96.981% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 228.177% |